Whitepapers, Posters & Presentations

White Papers

• 

  Stability of Plasmid DNA - A Review of the Data

  A review of stability data for plasmid pharmaceuticals accross typical storage temperatures and handling conditions.

• 

  Comparison of VGXI’s HD and GMP Services

  Side by side comparison of the differences between VGXI’s Highly Documented (HD) grade and full cGMP grade service levels for plasmid production.

• 

  Purity by A260/280

  In-depth review of the standard test method and inherent limitations for evaluating nucleic acid purity.

• 

  Determining Plasmid Quantity for your Clinical Trial

  Case studies are presented to illustrate how much plasmid is required at each stage of manufacturing – from bulk production through fill/finish and product stability studies.

• 

  5 Qualities to Look for in a CMO

  A review of five key qualities to look for when choosing a CMO to manufacture plasmid DNA for a clinical trial.

• 

  Plasmid DNA Manufacturing Timeline

  An overview of the typical steps and time required for completion of a GMP plasmid manufacturing campaign.

• 

  Kanamycin Concentration Reduction During the VGXI Process

  This white paper reviews how a common plasmid selection agent, Kanamycin, is removed during the VGXI purification process to levels that are undetectable by standard assay methods.

• 

  Single-Use Process Equipment

  White paper reviewing process and quality improvements possible through the use of single-use systems in biopharmaceutical manufacturing.

• 

  VGXI Pre-Clinical Production Service

  VGXI’s Pre-Clinical Production Service uses the same patented manufacturing technology as our GMP production.

• 

  VGXI HD Plasmid Production Service

  VGXI’s HD Production Service produces plasmids suitable for use as a raw material in cGMP viral vector manufacturing and toxicology studies.

• 

  VGXI cGMP Production Service

  VGXI's cGMP Production Service provides injectable-grade plasmid DNA suitable for human clinical trials and commercial supply.